Emile SH, Wignakumar A. Non-operative management of rectal cancer: Highlighting the controversies. World J Gastrointest Surg 2024; 16(6): 1501-1506 [PMID: PMC11230012 DOI: 10.4240/wjgs.v16.i6.1501]
Corresponding Author of This Article
Sameh Hany Emile, FACS, MD, MSc, PhD, Associate Professor, Research Scientist, Surgeon, Department of Colorectal Surgery, Cleveland Clinic Florida, 2950 Cleveland Clinic Blvd, Weston, FL 33331, United States. sameh200@hotmail.com
Research Domain of This Article
Surgery
Article-Type of This Article
Editorial
Open-Access Policy of This Article
This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
World J Gastrointest Surg. Jun 27, 2024; 16(6): 1501-1506 Published online Jun 27, 2024. doi: 10.4240/wjgs.v16.i6.1501
Non-operative management of rectal cancer: Highlighting the controversies
Sameh Hany Emile, Anjelli Wignakumar
Sameh Hany Emile, Anjelli Wignakumar, Department of Colorectal Surgery, Cleveland Clinic Florida, Weston, FL 33331, United States
Author contributions: Emile SH developed the concept and wrote the article; and Wignakumar A shared in the writing and critical revision of the manuscript.
Conflict-of-interest statement: All authors declare that they have no competing interests or financial relations to disclose.
Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/
Corresponding author: Sameh Hany Emile, FACS, MD, MSc, PhD, Associate Professor, Research Scientist, Surgeon, Department of Colorectal Surgery, Cleveland Clinic Florida, 2950 Cleveland Clinic Blvd, Weston, FL 33331, United States. sameh200@hotmail.com
Received: February 21, 2024 Revised: April 18, 2024 Accepted: April 23, 2024 Published online: June 27, 2024 Processing time: 129 Days and 16.5 Hours
Abstract
There remains much ambiguity on what non-operative management (NOM) of rectal cancer truly entails in terms of the methods to be adopted and the best algorithm to follow. This is clearly shown by the discordance between various national and international guidelines on NOM of rectal cancer. The main aim of the NOM strategy is organ preservation and avoiding unnecessary surgical intervention, which carries its own risk of morbidity. A highly specific and sensitive surveillance program must be devised to avoid patients undergoing unnecessary surgical interventions. In many studies, NOM, often interchangeably called the Watch and Wait strategy, has been shown as a promising treatment option when undertaken in the appropriate patient population, where a clinical complete response is achieved. However, there are no clear guidelines on patient selection for NOM along with the optimal method of surveillance.
Core Tip: Patients with locally advanced rectal cancers are ideally treated with neoadjuvant chemoradiation therapy followed by surgical resection. As neoadjuvant treatments evolved, an increasing number of patients showed a complete response to neoadjuvant therapy. The complete response of rectal cancers to neoadjuvant treatment inspired the concept of non-operative management (NOM). Following extensive multidisciplinary team meeting discussion, patients can be considered for NOM. Questions arose regarding patient selection for NOM and the best surveillance program to ensure no red flags for recurrent disease. Another consideration is how patients who develop recurrence be managed.